AUTHORS
Luke Zurbriggen, MD, David Farber, PharmD2, Natalia Petruski-Ivleva, PhD3, Gabrielle Miller, PhD, MPH4, Anthony Yu, PharmD, MS5, Jill Schinkel, MS6, Nancy El-Hoyek, PharmD, MSc7
AFFILIATIONS
1 University of Wisconsin, Madison, Wisconsin, United States
2 Sanofi, Cambridge, Massachusetts, United States
3 Sanofi, Cambridge, Massachusetts, United States
4 Inovalon, Decatur, Georgia, United States
5 Inovalon, Bowie, Maryland, United States
6 Inovalon, Ashburn, Virginia, United States
7 Sanofi, Cambridge, Massachusetts, United States
ABSTRACT
BACKGROUND: Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by complex immune dysregulation. Women of reproductive age (18–45 years) with ITP experience unique challenges related to pregnancy, heavy menstrual bleeding (HMB), abnormal uterine bleeding (AUB), among others. Limited real-world evidence exists around persistent or chronic ITP burden among women aged 18–45 years. The aim of this research was to describe patient characteristics, clinical outcomes, and corticosteroid use in this population compared to women without ITP.
METHODS: This study used the Inovalon MORE2 Registry® (January 2016–May 2026), a large United States (US) closed-claims database with commercial, Medicare Advantage, and managed Medicaid populations, Inovalon Social Drivers of Health Warehouse, and Veritas Fact of Death Database. Women aged 18–45 with persistent or chronic ITP initiating advanced therapy (thrombopoietin receptor agonists [TPO-RAs], rituximab, and fostamatinib) were identified (index on first advanced therapy claim). The inclusion criteria included ≥12 months continuous enrollment pre- and post-index, and ≥1 inpatient or ≥2 outpatient claims with ITP codes (ICD-10-CM D69.3) during baseline. Women with ITP were matched 1:5 to a random sample of women without ITP on age, sex, payer type, race/ethnicity, and calendar time (±90 days). Baseline comorbidities and clinical events were assessed during the 12-month baseline period. Post-index, the evaluated outcomes included bleeding events (e.g., HMB, AUB), venous and arterial thromboembolic events (VTE/ATE), other cardiovascular events, infections, mortality, and corticosteroid use. Event rates were calculated per 1,000 patient-years (PY). Descriptive statistics were used for the baseline characteristics. Multivariable regression models were used to compare rates of events adjusting for residual confounding.
RESULTS: Overall, 812 women aged 18–45 years with ITP were matched to 4,060 women without ITP. The mean age was 31.7 years (SD: 7.8), and 64.2% of women had primary ITP (35.8% had ≥1 secondary cause). During follow-up (median of 32.6 months), women with ITP treated with advanced therapy experienced higher bleeding rates: HMB occurred at 213.6/1,000 PY (196.5–231.8) in ITP vs. 60.0/1,000 PY (55.9–64.4) in referents; AUB rates were 122.6/1,000 PY in ITP vs. 62.2/1,000 PY (58.0–66.7) in referents (2.0-fold higher). After adjustment, the rate of HMB was 2.1-fold higher and that of AUB was 1.7-fold higher in ITP. Other bleeding events included: gastrointestinal bleeding (85.5 vs. 25.0/1,000 PY), hemorrhagic anemia (40.1 vs. 7.6/1,000 PY), and epistaxis (55.0 vs. 3.4/1,000 PY). Intracranial hemorrhage rate was 17.5/1,000 PY in women with ITP compared to 0.9/1,000 PY in matched referent. Composite any-bleeding-event rate was 864.6/1,000 PY in ITP vs. 301.3/1,000 PY in referents. The VTE rates were 48.7/1,000 PY (40.7–57.8) in ITP vs. 5.0/1,000 PY (3.9–6.4) in referents (9.7-fold higher); ATE rates were 27.5/1,000 PY (21.6–34.5) vs. 4.4/1,000 PY (3.4–5.7) (6.2-fold higher). After adjustment, the rate of VTE was 7.8-fold higher and that of ATE was 2.4-fold higher in ITP. The rate of heart failure (21.2 vs. 3.0/1,000 PY), atrial fibrillation (5.2 vs. 1.4/1,000 PY), and inpatient infections (35.7 vs. 7.5/1,000 PY) were higher in patients with ITP. All-cause mortality was 1.6% in ITP vs. 0.12% in referents during follow-up, and the mortality rate was 4.83 vs. 0.38 per 1,000 PY, approximately 12.7-fold higher. Systemic corticosteroid use was highly prevalent. After advanced therapy initiation, 70.0% of patients with ITP had ≥1 oral steroid fill, with a mean exposure of 42.2 days/PY among users, while 52.1% of users had extended use (>6 weeks). The Mean Prednisone-equivalent daily dose was 51.82 mg/day (SD: 63.8) among users during exposure.
CONCLUSIONS: Women aged 18–45 years with persistent or chronic ITP treated with TPO-RAs, rituximab, and fostamatinib experience a high disease burden characterized by elevated bleeding (particularly HMB and AUB), increased thromboembolic risk, persistent corticosteroid exposure, and increased mortality compared to matched non-ITP referents. These findings highlight significant unmet need in this population and underscore the clinical rationale for further disease control. Future research should investigate therapies which safely modulate the immune system, reduce corticosteroid exposure and disease burden.
DISCLOSURES
Luke Zurbriggen, MD: Sanofi - Honoraria; Sanofi - Research Funding